$HIMS
Hims & Hers Health, Inc.

2020 Form 10-K Financial Statement

#000119312521089657 Filed on March 22, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019 Q2
Revenue $148.8M $0.00
YoY Change 80.18%
Cost Of Revenue $39.31M
YoY Change 3.57%
Gross Profit $109.5M
YoY Change 145.38%
Gross Profit Margin 73.58%
Selling, General & Admin $65.61M $240.0K
YoY Change 17.44%
% of Gross Profit 59.94%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.057M
YoY Change 306.54%
% of Gross Profit 0.97%
Operating Expenses $124.6M $240.0K
YoY Change 4.68%
Operating Profit -$15.14M -$16.61K
YoY Change -79.65%
Interest Expense $10.00K $970.0K
YoY Change -97.29%
% of Operating Profit
Other Income/Expense, Net -$2.843M
YoY Change -216.52%
Pretax Income -$17.99M $730.0K
YoY Change -75.01%
Income Tax $127.0K
% Of Pretax Income
Net Earnings -$18.11M $730.0K -$16.61K
YoY Change -74.86%
Net Earnings / Revenue -12.18%
Basic Earnings Per Share -$0.51
Diluted Earnings Per Share -$0.51 $29.01K
COMMON SHARES
Basic Shares Outstanding 35.35M shares
Diluted Shares Outstanding 35.35M shares

Balance Sheet

Concept 2020 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.100M $1.500M
YoY Change -26.67%
Cash & Equivalents $1.100M $1.510M
Short-Term Investments
Other Short-Term Assets $100.0K $100.0K
YoY Change 0.0%
Inventory
Prepaid Expenses $147.5K
Receivables
Other Receivables
Total Short-Term Assets $1.100M $1.658M
YoY Change -35.29%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $204.5M $203.1M
YoY Change 0.69%
Other Assets $500.0K
YoY Change
Total Long-Term Assets $204.5M $203.1M
YoY Change 0.69%
TOTAL ASSETS
Total Short-Term Assets $1.100M $1.658M
Total Long-Term Assets $204.5M $203.1M
Total Assets $205.6M $204.8M $536.3K
YoY Change 0.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00 $18.48K $21.98K
YoY Change
Accrued Expenses $4.200M $478.6K $449.1K
YoY Change 740.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $100.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.900M $979.4K $527.9K
YoY Change 390.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.200M $7.200M
YoY Change 0.0%
Total Long-Term Liabilities $7.200M $7.200M $0.00
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.900M $979.4K $527.9K
Total Long-Term Liabilities $7.200M $7.200M $0.00
Total Liabilities $12.10M $8.173M $500.0K
YoY Change 47.56%
SHAREHOLDERS EQUITY
Retained Earnings $1.147M -$16.61K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $193.5M -$139.8M $0.00
YoY Change
Total Liabilities & Shareholders Equity $205.6M $204.8M $536.3K
YoY Change 0.39%

Cashflow Statement

Concept 2020 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income -$18.11M $730.0K -$16.61K
YoY Change -74.86%
Depreciation, Depletion And Amortization $1.057M
YoY Change 306.54%
Cash From Operating Activities -$2.479M -$30.00K $0.00
YoY Change -96.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions $0.00
YoY Change
Other Investing Activities $330.0K $0.00
YoY Change -100.16%
Cash From Investing Activities -$39.70M $0.00
YoY Change 1.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net $1.515M
YoY Change -83.26%
Cash From Financing Activities $47.74M -240.0K
YoY Change -49.91%
NET CHANGE
Cash From Operating Activities -$2.479M -30.00K 0.000
Cash From Investing Activities -$39.70M 0.000
Cash From Financing Activities $47.74M -240.0K
Net Change In Cash $5.553M -270.0K 0.000
YoY Change -129.45%
FREE CASH FLOW
Cash From Operating Activities -$2.479M -$30.00K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1058267
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
50100
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
147500
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1108367
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1657841
CY2020Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
204525055
CY2019Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
203107342
CY2020Q4 us-gaap Assets
Assets
205633422
CY2019Q4 us-gaap Assets
Assets
204765183
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
48194
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18475
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4189620
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
478577
CY2020Q4 hims Accrued Expensed Related Party Current
AccruedExpensedRelatedPartyCurrent
60000
CY2019Q4 hims Accrued Expensed Related Party Current
AccruedExpensedRelatedPartyCurrent
54839
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
598833
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
427503
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4896647
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
979394
CY2020Q4 hims Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7043750
CY2019Q4 hims Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7043750
CY2020Q4 hims Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
150000
CY2019Q4 hims Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
150000
CY2020Q4 us-gaap Liabilities
Liabilities
12090397
CY2019Q4 us-gaap Liabilities
Liabilities
8173144
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
188543020
CY2019Q4 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
191592030
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6901127
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3852147
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1901752
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1147262
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5000005
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5000009
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
205633422
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204765183
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4791727
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
710080
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-4791727
us-gaap Operating Income Loss
OperatingIncomeLoss
-710080
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1742713
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1857342
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3049014
us-gaap Net Income Loss
NetIncomeLoss
1147262
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1742713
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1857342
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-97400
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
147500
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6645
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
450081
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4171145
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18475
CY2020 hims Increase Decrease In Accrued Expensed Related Party
IncreaseDecreaseInAccruedExpensedRelatedParty
418577
hims Increase Decrease In Accrued Expensed Related Party
IncreaseDecreaseInAccruedExpensedRelatedParty
-54839
CY2020 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
171330
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-777074
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-241682
CY2020 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
325000
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
201250000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
325000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-201250000
hims Proceeds From Issuance Of Capital Units
ProceedsFromIssuanceOfCapitalUnits
201250000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6025000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4211257
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
203002023
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-452074
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1510341
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1510341
CY2020 hims Change In Value Of Class A Ordinary Shares Subject To Possible Redemption
ChangeInValueOfClassAOrdinarySharesSubjectToPossibleRedemption
-3049010
hims Change In Value Of Class A Ordinary Shares Subject To Possible Redemption
ChangeInValueOfClassAOrdinarySharesSubjectToPossibleRedemption
191592030
hims Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
-28496
hims Offering Costs Included In Notes Payable Related Party
OfferingCostsIncludedInNotesPayableRelatedParty
396720
CY2019Q3 hims Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P185D
hims Deferred Underwriting Commissions Recognized In Ipo
DeferredUnderwritingCommissionsRecognizedInIpo
7043750
hims Deferred Legal Fees Recognized In Ipo
DeferredLegalFeesRecognizedInIpo
150000
hims Offering Costs Paid By Sponsor In Exchange For Issuance Of Classb Ordinary Shares
OfferingCostsPaidBySponsorInExchangeForIssuanceOfClassbOrdinaryShares
-25000
CY2019Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
11900000
CY2020 hims Common Stock Shares Resale Or Transfer Share Price Threshold
CommonStockSharesResaleOrTransferSharePriceThreshold
12.00
CY2020 hims Advances From Related Party Agreed Amount
AdvancesFromRelatedPartyAgreedAmount
300000
CY2019Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
25000
CY2019Q2 hims Percentage Of Founder Shares On Outstanding Shares
PercentageOfFounderSharesOnOutstandingShares
0.20
CY2019Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.00
CY2020 hims Regulatory Withdrawal
RegulatoryWithdrawal
325000
CY2020 hims Proceeds From Issuance Of Founder Shares
ProceedsFromIssuanceOfFounderShares
25000
CY2020Q4 hims Advances From Related Party
AdvancesFromRelatedParty
62000
CY2019Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020 hims Annual Threshold Limit Regulatory Withdrawal
AnnualThresholdLimitRegulatoryWithdrawal
325000
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001773751
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
hims Capital Units Value Of Shares Issued During Period
CapitalUnitsValueOfSharesIssuedDuringPeriod
201250000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11855223
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6025000
us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
-191592030
CY2020 us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
3049010
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
92503
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
61720
CY2019Q3 hims Business Combination Requisites To Be Satisfied
BusinessCombinationRequisitesToBeSatisfied
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
CY2019Q3 hims Business Combination Covenants To Proceed With Business Combination
BusinessCombinationCovenantsToProceedWithBusinessCombination
In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination.
CY2019Q3 hims Description Of Results For Non Compliance With Business Combination
DescriptionOfResultsForNonComplianceWithBusinessCombination
The Company’s Sponsor, officers and directors (the “initial shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or July 22, 2021
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10000
CY2020Q4 us-gaap Cash
Cash
1100000
CY2020Q4 hims Working Capital Loan
WorkingCapitalLoan
0
CY2019Q4 hims Working Capital Loan
WorkingCapitalLoan
0
hims Annual Threshold Limit Regulatory Withdrawal
AnnualThresholdLimitRegulatoryWithdrawal
325000
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment.&#160;It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events.&#160;Accordingly, the actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 hims Common Stock Conversion Description
CommonStockConversionDescription
20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity- linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans.
CY2020 hims Restricted Investments Term
RestrictedInvestmentsTerm
P185D
CY2020Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Registrant Name
EntityRegistrantName
Hims & Hers Health, Inc.
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 dei Entity Public Float
EntityPublicFloat
204671250
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 hims Working Capital
WorkingCapital
3800000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000000

Files In Submission

Name View Source Status
0001193125-21-089657-index-headers.html Edgar Link pending
0001193125-21-089657-index.html Edgar Link pending
0001193125-21-089657.txt Edgar Link pending
0001193125-21-089657-xbrl.zip Edgar Link pending
d27413d10k.htm Edgar Link pending
d27413dex311.htm Edgar Link pending
d27413dex312.htm Edgar Link pending
d27413dex321.htm Edgar Link pending
d27413dex322.htm Edgar Link pending
d27413dex44.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hims-20201231.xml Edgar Link completed
hims-20201231.xsd Edgar Link pending
hims-20201231_cal.xml Edgar Link unprocessable
hims-20201231_def.xml Edgar Link unprocessable
hims-20201231_lab.xml Edgar Link unprocessable
hims-20201231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending